<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03009474</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_EXR_102</org_study_id>
    <nct_id>NCT03009474</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study of CJ-30060 After Single Dose Administration in Health Male Volunteers</brief_title>
  <official_title>Clinical Trial to Assess the Pharmacokinetic Characteristics of CJ-30060 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pharmacokinetics and safety after a single dose administration of CJ-30060 and
      Exforge® 5/160mg, Crestor 10mg in healthy male volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the pharmacokinetics and safety after a single dose
      administration of CJ-30060 and Exforge® 5/160mg, Crestor 10mg in healthy male volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of amlodipine, valsartan, rosuvastatin</measure>
    <time_frame>Up to 144 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of amlodipine, valsartan, rosuvastatin</measure>
    <time_frame>Up to 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration (Tmax) of amlodipine, valsartan, rosuvastatin</measure>
    <time_frame>Up to 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (t1/2) of amlodipine, valsartan, rosuvastatin</measure>
    <time_frame>Up to 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral clearance (CL/F) of amlodipine, valsartan, rosuvastatin</measure>
    <time_frame>Up to 144 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vd/F) of amlodipine, valsartan, rosuvastatin</measure>
    <time_frame>Up to 144 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>CJ-30060</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine 5 mg/ Valsartan 160 mg/ Rosuvastatin 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exforge tab 5/160mg, Crestor tab 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine 5 mg/ Valsartan 160 mg/ Rosuvastatin 10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-30060</intervention_name>
    <description>Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg</description>
    <arm_group_label>Exforge tab 5/160mg, Crestor tab 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exforge tab 5/160mg, Crestor tab 10mg</intervention_name>
    <description>Co-administration of Amlodipine 5 mg/ Valsartan 160 mg(combination drug) and Rosuvastatin 10 mg</description>
    <arm_group_label>CJ-30060</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male aged 20 to 45 years at the screening

          -  Subject who is over 50kg with BMI between 18 kg/m2 to 29 kg/m2 (inclusive)

          -  Subject who fully understood after being informed detailed description of clinical
             trial, written informed consent voluntarily to observe the precautions.

        Exclusion Criteria:

          -  Subject who has a medical history of severe cardiovascular, respiratory,
             hepatobiliary, renal disease hematologic, gastrointestinal, endocrinological,
             immunologic, dermatosis or neuropsychologic disease.

          -  Subject who have symptoms, result from acute disease within 28days before first
             administration.

          -  Subject who have chronic persisting disease with clinical significance.

          -  Subject who fall under the criteria below in laboratory test.

               -  AST/ALT &gt; UNL (upper normal limit) x 2

               -  Total bilirubin &gt; UNL x 1.5

               -  In case of renal failure that creatine clearance is less than 50mL/min according
                  to Cockcroft-Gault

               -  CPK &gt; UNL x 2.5

          -  Subject who with low blood pressure with clinical significance at screening test.

        (systolic blood pressure is less than 90 mmHg and diastolic blood pressure is less than 60
        mmHg)

          -  Subject with any positive reaction in HBs Ag, anti-HCV Ab, anti-HIV Ab, VDRL tests.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Young Park, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2015</study_first_submitted>
  <study_first_submitted_qc>January 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2017</study_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Amlodipine, Valsartan Drug Combination</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

